DV
Dividend Vision

AGMB — AgomAb Therapeutics NV American Depositary Shares

AgomAb Therapeutics NV American Depositary Shares (AGMB)

Total return is -17.4% over the past 0.5 years, 32.6 points behind SPY at 15.2%.

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company developing disease-modifying therapies for immunology and inflammatory diseases, with a pipeline including oral and inhaled small molecule inhibitors of ALK5/TGFßR1 for conditions such as Fibrostenosing Crohn's disease and idiopathic pulmonary fibrosis, along with a monoclonal antibody candidate targeting the MET receptor. The company does not currently distribute dividends. AgomAb appeals to investors seeking exposure to early-stage biotech development with no current income component, as the company remains in clinical trial phases with no approved products yet commercialized.

AGMB key facts

Asset type
Stock
Asset class
Equity
Inception date
02/05/2026
Last close
$13.22
Market cap
$592,945,600
Average volume
42000.0
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.46